Efficacy and Feasibility of Edoxaban Therapy without Prior Parenteral Anticoagulants in Patients with Venous Thromboembolism.
作者信息
Kataoka Naoya, Imamura Teruhiko
机构信息
Second Department of Internal Medicine, University of Toyama, Japan.
出版信息
Intern Med. 2024 Nov 1;63(21):3013. doi: 10.2169/internalmedicine.3366-23. Epub 2024 Mar 4.
Abstract
摘要
相似文献
1
Efficacy and Feasibility of Edoxaban Therapy without Prior Parenteral Anticoagulants in Patients with Venous Thromboembolism.
Intern Med. 2024 Nov 1;63(21):3013. doi: 10.2169/internalmedicine.3366-23. Epub 2024 Mar 4.
2
Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.
J Thromb Haemost. 2019 Oct;17(10):1694-1706. doi: 10.1111/jth.14548. Epub 2019 Jul 23.
3
Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
Lancet Haematol. 2016 Sep;3(9):e437-45. doi: 10.1016/S2352-3026(16)30080-1.
4
Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Vasc Health Risk Manag. 2014 Nov 7;10:627-39. doi: 10.2147/VHRM.S50543. eCollection 2014.
5
Thromboembolic Events While Taking Direct Oral Anticoagulants: An Analysis of Post-market WHO Database Reports from 2012 to 2020.
Clin Drug Investig. 2022 Jul;42(7):593-598. doi: 10.1007/s40261-022-01165-3. Epub 2022 Jun 8.
6
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31.
7
Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
Vasc Med. 2016 Aug;21(4):361-8. doi: 10.1177/1358863X16645853. Epub 2016 May 10.
8
Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain.
J Med Econ. 2022 Jan-Dec;25(1):840-847. doi: 10.1080/13696998.2022.2087998.
9
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Lancet Haematol. 2016 Aug;3(8):e379-87. doi: 10.1016/S2352-3026(16)30057-6. Epub 2016 Jul 1.
10
ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.
Thromb Res. 2020 Dec;196:297-304. doi: 10.1016/j.thromres.2020.09.001. Epub 2020 Sep 12.
本文引用的文献
1
Real-world Safety and Effectiveness of Edoxaban in Patients with Venous Thromboembolism with or without Preceding Parenteral Anticoagulants: A Single-center Retrospective Study.
Intern Med. 2024 Jul 1;63(13):1845-1853. doi: 10.2169/internalmedicine.2524-23. Epub 2023 Nov 20.
2
Acute pulmonary embolism and cancer: findings from the COPE study.
Clin Res Cardiol. 2024 Feb;113(2):288-300. doi: 10.1007/s00392-023-02323-z. Epub 2023 Nov 15.
3
Current venous thromboembolism management and outcomes in Japan.
Circ J. 2014;78(3):708-17. doi: 10.1253/circj.cj-13-0886. Epub 2014 Jan 7.
Zotero 插件